Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antihistamine pricing

This article was originally published in The Tan Sheet

Executive Summary

Aventis' Allegra, Schering-Plough's Clarinex, Pfizer's Zyrtec likely will "be moved to a higher tier of co-payment in terms of...managed care formularies" with out-of-pocket costs "being in the range of $25 to $30" when Schering's Claritin switches OTC, Aventis Investor Relations Director Arvind Sood predicts during Q2 analysts call July 31. However, with a monthly supply of Claritin expected to cost about the same, the likelihood that Allegra customers will switch to Claritin "is going to be minimal," Sood maintains...

You may also be interested in...



In Flood Of 2020 Sanitizer Launches, Unilever’s Suave Brand Tops US Category Sales

Unilever’s Suave brand led new sanitizer product sales in 2020, when hand sanitizers total sales grew 569%, according to IRI. Sales of rinseable hand-soap sales grew 64% and antiseptics 19%.

Turkish Medtechs Face The Constant Challenge Of Sailing In Stormy Seas

The pandemic has exacerbated the problems of the Turkish medical device industry, which was already struggling for survival and growth in a hostile policy environment. Local blood bag manufacturer Kansuk Laboratory talked to Medtech Insight about the difficulties it faces.

Pipeline Watch: Phase III Readouts For COVID-19, Dry Eye Disease, Uveal Melanoma

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

UsernamePublicRestriction

Register

PS094344

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel